Media coverage about Akebia Therapeutics (NASDAQ:AKBA) has been trending somewhat positive on Saturday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Akebia Therapeutics earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 75 out of 100, indicating that recent press coverage is likely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Share Activity Lifted for Akebia Therapeutics Inc (AKBA) in Session – Stock Press Daily (stockpressdaily.com)
- The Russell Investments Group Ltd. Raises Stake in Intel Corporation (NASDAQ:INTC) (ismboard.com)
- Akebia Therapeutics, Inc. (AKBA) registers a price change of -1.85% while Varex Imaging Corporation (VREX) finishes … – Stocks Gallery (stocksgallery.com)
- Akebia Therapeut Up 39.9% Since SmarTrend Uptrend Call (AKBA) (mysmartrend.com)
- ETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017 (finance.yahoo.com)
Akebia Therapeutics (NASDAQ AKBA) traded up 0.83% during midday trading on Friday, reaching $13.40. 275,292 shares of the company were exchanged. Akebia Therapeutics has a 52-week low of $7.16 and a 52-week high of $16.54. The firm’s 50-day moving average price is $14.42 and its 200 day moving average price is $11.63. The stock’s market capitalization is $245.22 million.
Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $1.00. The firm had revenue of $20.87 million during the quarter, compared to analyst estimates of $16.50 million. Equities analysts predict that Akebia Therapeutics will post ($3.46) earnings per share for the current year.
Several research firms have weighed in on AKBA. BidaskClub downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Zacks Investment Research downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. HC Wainwright dropped their target price on shares of Akebia Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Monday, July 10th. Aegis restated a “buy” rating on shares of Akebia Therapeutics in a report on Friday, June 30th. Finally, ValuEngine upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. Akebia Therapeutics presently has an average rating of “Hold” and an average price target of $18.25.
COPYRIGHT VIOLATION WARNING: This article was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/07/29/akebia-therapeutics-akba-receiving-somewhat-positive-news-coverage-analysis-finds-updated-updated-updated.html.
In other Akebia Therapeutics news, Director Muneer A. Satter acquired 1,034,482 shares of the business’s stock in a transaction dated Wednesday, July 5th. The shares were acquired at an average price of $14.50 per share, for a total transaction of $14,999,989.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 7.95% of the company’s stock.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.